All of the molecules currently under development have extensive human experience. In addition, the human disease under study is also found in animals, making animal study highly translatable to human study. Preparation is underway for formulation development and human dosing studies with ATB223 and ATB338. A veterinary indication is envisioned for ATB224. Fortunately, the Phase 2 programs required for these molecules are expected to be relatively short. Molecules and indications are currently confidential.